Qualigen Therapeutics Inc (QLGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 03-2021 | |
| Sales | 0 | 0 | 0 | 5,654 | 0 |
| Cost of Goods | N/A | N/A | N/A | 4,333 | N/A |
| Gross Profit | N/A | N/A | N/A | 1,321 | N/A |
| Operating Expenses | 5,762 | 11,305 | 14,761 | 24,317 | 0 |
| Operating Income | -5,762 | -11,305 | -14,761 | -22,663 | N/A |
| Interest Expense | 909 | 1,525 | 34 | -43 | 0 |
| Other Income | 518 | 350 | 907 | 4,729 | 0 |
| Pre-tax Income | -6,153 | -12,480 | -13,888 | -17,892 | 0 |
| Income Tax | 6 | -5 | 7 | 5 | N/A |
| Net Income Continuous | -6,159 | -12,475 | -13,895 | -17,897 | N/A |
| Net Income Discontinuous | -100 | -1,285 | -7,140 | N/A | N/A |
| Minority Interests | N/A | -343 | -2,394 | N/A | N/A |
| Net Income | $-6,259 | $-13,417 | $-18,641 | $-17,897 | $N/A |
| EPS Basic Total Ops | -17.55 | -132.25 | -242.70 | -305.00 | N/A |
| EPS Basic Continuous Ops | -17.27 | -122.93 | -181.00 | -305.05 | N/A |
| EPS Basic Discontinuous Ops | -0.28 | -9.32 | -62.00 | N/A | N/A |
| EPS Diluted Total Ops | -17.55 | -132.25 | -242.70 | -305.00 | N/A |
| EPS Diluted Continuous Ops | -17.27 | -122.93 | -181.00 | -305.05 | N/A |
| EPS Diluted Discontinuous Ops | -0.28 | -9.32 | -62.00 | N/A | N/A |
| EPS Diluted Before Non-Recurring Items | -17.27 | -123.00 | -242.50 | -385.00 | N/A |
| EBITDA(a) | $-5,146 | $-9,831 | $-14,749 | $-22,325 | $N/A |